Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.
作者信息
Kushnirsky Marina, Feun Lynn G, Gultekin Sakir H, de la Fuente Macarena I
机构信息
Department of Neurology, University of Miami, Miami, FL.
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
出版信息
JCO Precis Oncol. 2020 Feb 3;4. doi: 10.1200/PO.19.00272. eCollection 2020.
Abstract
摘要
相似文献
1
Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.在BRAF突变型胶质母细胞瘤中，BRAF抑制剂治疗失败后，达拉非尼和曲美替尼联合使用可实现长期完全缓解
JCO Precis Oncol. 2020 Feb 3;4. doi: 10.1200/PO.19.00272. eCollection 2020.
2
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.与I型RAF抑制剂相比，II型RAF抑制剂在表达肺癌中常见的不同BRAF突变类型的细胞中能更有效地抑制ERK通路。
Oncotarget. 2018 Feb 27;9(22):16110-16123. doi: 10.18632/oncotarget.24576. eCollection 2018 Mar 23.
3
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.达拉非尼联合曲美替尼，或单药用于治疗 BRAF 突变型转移性黑色素瘤。
Clin Cancer Res. 2014 Apr 15;20(8):2035-43. doi: 10.1158/1078-0432.CCR-13-2054. Epub 2014 Feb 28.
4
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.达拉非尼和曲美替尼联合抑制BRAF和MEK在BRAF V600突变型结直肠癌中的应用
J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.
5
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.达拉非尼联合曲美替尼治疗 BRAF 和 MEK 抑制剂预处理的晚期 BRAF 突变型黑色素瘤患者：一项开放标签、单臂、双中心、Ⅱ期临床研究。
Lancet Oncol. 2017 Apr;18(4):464-472. doi: 10.1016/S1470-2045(17)30171-7. Epub 2017 Mar 4.
6
Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.曲美替尼（迈吉宁®）：用于治疗转移性或不可切除的BRAF V600阳性黑色素瘤，延长数月生命。
Prescrire Int. 2016 Dec;25(177):285-288.
7
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.达拉非尼联合曲美替尼治疗 BRAF V600E 突变型甲状腺未分化癌患者：来自 II 期 ROAR 篮子研究的更新分析。
Ann Oncol. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014. Epub 2022 Jan 10.
8
Complete response of metastatic V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report.辅助性达拉非尼和曲美替尼治疗后转移性V600突变型间变性甲状腺癌完全缓解：一例报告
World J Clin Cases. 2023 Sep 26;11(27):6664-6669. doi: 10.12998/wjcc.v11.i27.6664.
9
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
10
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.在接受单药BRAF抑制剂治疗后病情进展的BRAFV600突变型黑色素瘤患者中联合使用BRAF抑制剂（达拉非尼）和MEK抑制剂（曲美替尼）。
J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.
引用本文的文献
1
MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions.胶质母细胞瘤中的MEK抑制：当前观点与未来方向
Int J Mol Sci. 2025 Jul 17;26(14):6875. doi: 10.3390/ijms26146875.
2
Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case.伴有软脑膜转移的高级别胶质瘤对BRAF/MEK抑制剂治疗在2周内出现快速反应：病例说明
J Neurosurg Case Lessons. 2025 Jul 7;10(1). doi: 10.3171/CASE25247.
3
Single-cell multi-omics analysis reveals candidate therapeutic drugs and key transcription factor specifically for the mesenchymal subtype of glioblastoma.单细胞多组学分析揭示了专门针对胶质母细胞瘤间充质亚型的候选治疗药物和关键转录因子。
Cell Biosci. 2024 Dec 20;14(1):151. doi: 10.1186/s13578-024-01332-3.
4
The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.达拉非尼联合曲美替尼治疗 BRAF V600 突变型脑胶质瘤的疗效：系统评价和荟萃分析。
Neurosurg Rev. 2024 Aug 22;47(1):458. doi: 10.1007/s10143-024-02664-x.
5
Glioblastoma Therapy: Past, Present and Future.胶质母细胞瘤治疗：过去、现在和未来。
Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529.
6
BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience.BRAF介导的成人和儿童脑肿瘤：综述及澳大利亚和新西兰的经验
Front Oncol. 2023 Apr 14;13:1154246. doi: 10.3389/fonc.2023.1154246. eCollection 2023.
7
Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution.BRAF V600E突变在胶质瘤中的意义：分子考量、预后价值及治疗进展
Front Oncol. 2023 Jan 4;12:1067252. doi: 10.3389/fonc.2022.1067252. eCollection 2022.
8
Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature.一线使用BRAF/MEK抑制剂治疗高级别胶质瘤：一例病例报告及文献综述
Neurooncol Adv. 2022 Nov 19;4(1):vdac174. doi: 10.1093/noajnl/vdac174. eCollection 2022 Jan-Dec.
9
New Directions in the Therapy of Glioblastoma.胶质母细胞瘤治疗的新方向
Cancers (Basel). 2022 Oct 31;14(21):5377. doi: 10.3390/cancers14215377.
10
Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI.通过术前MRI上的环形强化表现预测多形性胶质母细胞瘤中的BRAF突变状态。
Front Oncol. 2022 Aug 8;12:937345. doi: 10.3389/fonc.2022.937345. eCollection 2022.
本文引用的文献
1
Sustained response of three pediatric BRAF mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.三名BRAF突变的儿童高级别胶质瘤患者对BRAF和MEK抑制剂联合治疗的持续反应。
Oncotarget. 2019 Jan 11;10(4):551-557. doi: 10.18632/oncotarget.26560.
2
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.RAF 抑制剂 PLX8394 选择性地破坏 BRAF 二聚体和 RAS 非依赖性 BRAF 突变驱动的信号转导。
Nat Med. 2019 Feb;25(2):284-291. doi: 10.1038/s41591-018-0274-5. Epub 2018 Dec 17.
3
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.CBTRUS统计报告：2011 - 2015年美国原发性脑肿瘤及其他中枢神经系统肿瘤诊断情况
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131.
4
BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study.BRAF 抑制剂治疗 - 突变型神经胶质瘤：VE-BASKET 研究结果。
J Clin Oncol. 2018 Dec 10;36(35):3477-3484. doi: 10.1200/JCO.2018.78.9990. Epub 2018 Oct 23.
5
BRAF alterations in primary brain tumors.原发性脑肿瘤中的BRAF改变。
Discov Med. 2018 Aug;26(141):51-60.
6
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.癌症中 BRAF 改变的分类：可操作突变的新合理治疗策略。
Oncogene. 2018 Jun;37(24):3183-3199. doi: 10.1038/s41388-018-0171-x. Epub 2018 Mar 15.
7
Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With -Mutated High-Grade Glioma.达拉非尼联合曲美替尼治疗携带 BRAF V600E 突变的高级别胶质瘤成人患者的快速临床和影像学反应。
J Natl Compr Canc Netw. 2018 Jan;16(1):4-10. doi: 10.6004/jnccn.2017.7032.
8
Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.上皮样胶质母细胞瘤经综合分子分析可分层为既定的诊断亚型。
Brain Pathol. 2018 Sep;28(5):656-662. doi: 10.1111/bpa.12566. Epub 2017 Oct 30.
9
Dabrafenib and trametinib in BRAFV600E mutated glioma.达拉非尼和曲美替尼用于BRAFV600E突变型胶质瘤
CNS Oncol. 2017 Oct;6(4):291-296. doi: 10.2217/cns-2017-0006. Epub 2017 Oct 6.
10
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.达拉非尼联合曲美替尼与达拉非尼单药治疗转移性BRAF V600E/K突变黑色素瘤患者：一项3期研究的长期生存和安全性分析
Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.
Zotero 插件